Clinical trials
Observational Infertility trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Unknown status | 11 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Reproductive & Genetic Hospital of CITIC-Xiangya | 3 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 2 |
| Peking University Third Hospital | 2 |
| Shengjing Hospital | 2 |
| Tang-Du Hospital | 2 |
| Women's Hospital School Of Medicine Zhejiang University | 2 |
| Chinese Medical Association | 1 |
| Ferring Pharmaceuticals | 1 |
| First Affiliated Hospital, Sun Yat-Sen University | 1 |
| Guangzhou Women and Children's Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Infertility | 31 |
| Anxiety Disorders | 2 |
| Abortion, Habitual | 1 |
| Abortion, Spontaneous | 1 |
| Endometriosis | 1 |
| Infertility, Female | 1 |
| Latent Tuberculosis | 1 |
| Leiomyoma | 1 |
| Neoplasms | 1 |
| Oligospermia | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.